Maria Gonzalez

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study

Georgina V. Long, Victoria Atkinson, Serigne Lo et al. · The Lancet Oncology · 2018 · 996 citations

Medicine, Immunology, Oncology +13

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

Elisa A. Rozeman, Alexander M. Menzies, Alexander C. J. van Akkooi et al. · The Lancet Oncology · 2019 · 522 citations

Pharmacy, Oncology, Pharmacokinetics +16

Orchestrated Intron Retention Regulates Normal Granulocyte Differentiation

Justin Wong, William Ritchie, Olivia A. Ebner et al. · Cell · 2013 · 500 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +6

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

Irene L. M. Reijers, Alexander M. Menzies, Alexander C. J. van Akkooi et al. · Nature Medicine · 2022 · 357 citations · Full text

Medicine, Oncology, Surgery +17

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

Elisa A. Rozeman, Esmée P. Hoefsmit, Irene L. M. Reijers et al. · Nature Medicine · 2021 · 337 citations · Full text

Medicine, Clinical Sciences, Oncology +16